Copanlisib With Dose-Adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and Other High-Grade B-cell Lymphomas
Phase 1 Terminated
8 enrolled 17 charts
huJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia
Phase 1 Terminated
55 enrolled
Ipilimumab and Local Radiation for Selected Solid Tumors
Phase 1 Terminated
3 enrolled 5 charts
Rituximab Hyaluronidase in Combination With Chemotherapy in Treating Aggressive B-cell Lymphoma in Uganda
Phase 1 Terminated
18 enrolled
Pilot Study of Autologous Anti-CD22 Chimeric Antigen Receptor Redirected T Cells In Patients With Chemotherapy Resistant Or Refractory Acute Lymphoblastic Leukemia
Phase 1 Terminated
5 enrolled
RPM CD19-mbIL15-CAR-T Cells in Patient With Advanced Lymphoid Malignancies
Phase 1 Terminated
2 enrolled
CD19-Specific T Cells Post AlloSCT
Phase 1 Terminated
4 enrolled
Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid Malignancies
Phase 1 Terminated
2 enrolled 6 charts
Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies
Phase 1 Terminated
5 enrolled
Dasatinib for Modulating Immune System After Autologous Stem Cell Transplants for Multiple Myeloma, Non-Hodgkin, or Hodgkin Lymphoma
Phase 1 Terminated
8 enrolled
Immunotoxin Therapy and Cytarabine in Treating Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia
Phase 1 Terminated
18 enrolled
CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Phase 1 Terminated
1 enrolled
Antibody Therapy in Treating Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
Phase 1 Terminated
3 enrolled 3 charts
Umbilical Cord Blood T-Regulatory Cell Infusion Followed by Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Leukemia or Other Hematologic Diseases
Phase 1 Terminated
3 enrolled
Biological Therapies Following Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma, Hodgkin's Disease, or Advanced Breast Cancer
Phase 1 Terminated
Donor T Cells in Treating Patients With High-Risk Hematologic Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant
Phase 1 Terminated
3 enrolled
A Phase I Study of Alisertib + R-EPOCH for Treatment of Myc-Positive Aggressive B-cell Lymphomas
Phase 1 Terminated
1 enrolled
506U78 in Treating Patients With Hematologic Cancer and Kidney or Liver Impairment
Phase 1 Terminated
10 enrolled
Safety Study of ON 013105 in Lymphoma and Acute Lymphoid Leukemia
Phase 1 Terminated
7 enrolled
Lenalidomide And Rituximab as Maintenance Therapy in Treating Patients With B-Cell Non-Hodgkin Lymphoma
Phase 1 Terminated
5 enrolled
Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection
Phase 1 Terminated
72 enrolled
Sirolimus in Treating Young Patients With Relapsed or Refractory Acute Leukemia or Non-Hodgkin's Lymphoma
Phase 1 Terminated
10 enrolled
Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia
Phase 1 Terminated
129 enrolled
Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia
Phase 1 Terminated
22 enrolled
Tanespimycin and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas
Phase 1 Terminated
36 enrolled
Oxaliplatin, Ifosfamide and Etoposide in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma
Phase 1 Terminated
40 enrolled
Geldanamycin Analogue in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma
Phase 1 Terminated
45 enrolled
Irradiated Donor Lymphocytes and Rituximab in Treating Patients With Relapsed or Refractory Lymphoproliferative Disease
Phase 1 Terminated
2 enrolled
Partially HLA-Matched Irradiated Allogeneic Cellular Therapy After Reduced Intensity Total Body Irradiation
Phase 1 Terminated
4 enrolled
PXD101 and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma
Phase 1 Terminated
36 enrolled
Beta-Glucan and Rituximab in Treating Young Patients With Relapsed or Progressive Lymphoma or Leukemia, or Lymphoproliferative Disorder Related to Donor Stem Cell Transplantation
Phase 1 Terminated
3 enrolled
Radiolabeled Monoclonal Antibody With or Without Peripheral Stem Cell Transplantation in Treating Children With Recurrent or Refractory Lymphoma
Phase 1 Terminated
36 enrolled
SB-715992 in Treating Patients With Metastatic or Unresectable Solid Tumors or Hodgkin's or Non-Hodgkin's Lymphoma
Phase 1 Terminated
31 enrolled
Peripheral Stem Cell Transplantation to Prevent Neutropenia in Patients Receiving Chemotherapy for Relapsed or Refractory Non-Hodgkin's Lymphoma
Phase 1 Terminated
3 enrolled
Topotecan in Treating Young Patients With Neoplastic Meningitis Due to Leukemia, Lymphoma, or Solid Tumors
Phase 1 Terminated
19 enrolled
Vorinostat and Lenalidomide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma
Phase 1 Terminated
30 enrolled
Gene Therapy and Chemotherapy in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma
Phase 1 Terminated
8 enrolled
12-O-Tetradecanoylphorbol-13-acetate in Treating Patients With Hematologic Cancer or Bone Marrow Disorder
Phase 1 Terminated